
Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 6, 21, 21, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 6, 21, 21, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hypopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypopharyngeal Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypopharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
161 Pages
- Introduction
- Global Markets Direct Report Coverage
- Hypopharyngeal Cancer – Overview
- Hypopharyngeal Cancer – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypopharyngeal Cancer – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypopharyngeal Cancer – Companies Involved in Therapeutics Development
- Akeso Inc
- Ascenta Therapeutics Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- BioAtla Inc
- Biomimetix JV LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Checkmate Pharmaceuticals Inc
- Compugen Ltd
- CSPC Pharmaceutical Group Ltd
- Dracen Pharmaceuticals Inc
- Eisai Co Ltd
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Genentech USA Inc
- Genexine Inc
- Genocea Biosciences Inc
- GlaxoSmithKline Plc
- I-Mab
- Incyte Corp
- Innate Pharma SA
- IO Biotech Inc
- Istari Oncology Inc
- Jiangsu Hengrui Medicine Co Ltd
- Mabpharm Ltd
- Merck & Co Inc
- Moderna Inc
- Oncolys BioPharma Inc
- Ono Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- RemeGen Co Ltd
- Rubius Therapeutics Inc
- Sanofi
- Scancell Holdings Plc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shattuck Labs Inc
- VasGene Therapeutics Inc
- Hypopharyngeal Cancer – Drug Profiles
- (IO-102 + IO-103) – Drug Profile
- Product Description
- Mechanism Of Action
- adavosertib – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- afatinib dimaleate – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ASTX-660 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- atezolizumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- autogene cevumeran – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BI-765063 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BI-836880 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-986207 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMX-001 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- camrelizumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cemiplimab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- COM-701 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dalpiciclib – Drug Profile
- Product Description
- Mechanism Of Action
- DN-1508052 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- docetaxel albumin bound – Drug Profile
- Product Description
- Mechanism Of Action
- durvalumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- E-7130 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- efineptakin alfa – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ezabenlimab – Drug Profile
- Product Description
- Mechanism Of Action
- feladilimab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GEN-009 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- INCA-00186 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lenvatinib mesylate – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ligufalimab – Drug Profile
- Product Description
- Mechanism Of Action
- MK-4830 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Modi-1 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- monalizumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mRNA-4157 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nivolumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nivolumab biosimilar – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Oncolytic Virus to Target CD155/NECL5 for Solid Tumors – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ozuriftamab vedotin – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pembrolizumab – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- penpulimab – Drug Profile
- PGV-001 – Drug Profile
- ragifilimab – Drug Profile
- RC-108 – Drug Profile
- RTX-321 – Drug Profile
- ruxolitinib phosphate – Drug Profile
- SAR-444245 – Drug Profile
- SB-11285 – Drug Profile
- sirpiglenastat – Drug Profile
- SL-279252 – Drug Profile
- suratadenoturev – Drug Profile
- tiragolumab – Drug Profile
- toripalimab – Drug Profile
- ulevostinag – Drug Profile
- uliledlimab – Drug Profile
- Vas-01 – Drug Profile
- vidutolimod – Drug Profile
- xevinapant – Drug Profile
- Hypopharyngeal Cancer – Dormant Projects
- Hypopharyngeal Cancer – Discontinued Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Hypopharyngeal Cancer, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 11: Number of Products by Stage and Mechanism of Action, 2022
- Table 12: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 13: Number of Products by Stage and Route of Administration, 2022
- Table 14: Number of Products by Stage and Molecule Type, 2022
- Table 15: Hypopharyngeal Cancer – Pipeline by Akeso Inc, 2022
- Table 16: Hypopharyngeal Cancer – Pipeline by Ascenta Therapeutics Inc, 2022
- Table 17: Hypopharyngeal Cancer – Pipeline by Astex Pharmaceuticals Inc, 2022
- Table 18: Hypopharyngeal Cancer – Pipeline by AstraZeneca Plc, 2022
- Table 19: Hypopharyngeal Cancer – Pipeline by BioAtla Inc, 2022
- Table 20: Hypopharyngeal Cancer – Pipeline by Biomimetix JV LLC, 2022
- Table 21: Hypopharyngeal Cancer – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 22: Hypopharyngeal Cancer – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 23: Hypopharyngeal Cancer – Pipeline by Checkmate Pharmaceuticals Inc, 2022
- Table 24: Hypopharyngeal Cancer – Pipeline by Compugen Ltd, 2022
- Table 25: Hypopharyngeal Cancer – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 26: Hypopharyngeal Cancer – Pipeline by Dracen Pharmaceuticals Inc, 2022
- Table 27: Hypopharyngeal Cancer – Pipeline by Eisai Co Ltd, 2022
- Table 28: Hypopharyngeal Cancer – Pipeline by F-star Therapeutics Inc, 2022
- Table 29: Hypopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 30: Hypopharyngeal Cancer – Pipeline by Genentech USA Inc, 2022
- Table 31: Hypopharyngeal Cancer – Pipeline by Genexine Inc, 2022
- Table 32: Hypopharyngeal Cancer – Pipeline by Genocea Biosciences Inc, 2022
- Table 33: Hypopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, 2022
- Table 34: Hypopharyngeal Cancer – Pipeline by I-Mab, 2022
- Table 35: Hypopharyngeal Cancer – Pipeline by Incyte Corp, 2022
- Table 36: Hypopharyngeal Cancer – Pipeline by Innate Pharma SA, 2022
- Table 37: Hypopharyngeal Cancer – Pipeline by IO Biotech Inc, 2022
- Table 38: Hypopharyngeal Cancer – Pipeline by Istari Oncology Inc, 2022
- Table 39: Hypopharyngeal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 40: Hypopharyngeal Cancer – Pipeline by Mabpharm Ltd, 2022
- Table 41: Hypopharyngeal Cancer – Pipeline by Merck & Co Inc, 2022
- Table 42: Hypopharyngeal Cancer – Pipeline by Moderna Inc, 2022
- Table 43: Hypopharyngeal Cancer – Pipeline by Oncolys BioPharma Inc, 2022
- Table 44: Hypopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Table 45: Hypopharyngeal Cancer – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 46: Hypopharyngeal Cancer – Pipeline by RemeGen Co Ltd, 2022
- Table 47: Hypopharyngeal Cancer – Pipeline by Rubius Therapeutics Inc, 2022
- Table 48: Hypopharyngeal Cancer – Pipeline by Sanofi, 2022
- Table 49: Hypopharyngeal Cancer – Pipeline by Scancell Holdings Plc, 2022
- Table 50: Hypopharyngeal Cancer – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
- Table 51: Hypopharyngeal Cancer – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 52: Hypopharyngeal Cancer – Pipeline by Shattuck Labs Inc, 2022
- Table 53: Hypopharyngeal Cancer – Pipeline by VasGene Therapeutics Inc, 2022
- Table 54: Hypopharyngeal Cancer – Dormant Projects, 2022
- Table 55: Hypopharyngeal Cancer – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Hypopharyngeal Cancer, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Top 10 Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Top 10 Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.